Video: 90 Seconds With… Mark Diamond, Antisense Therapeutics
Got 90 seconds? Then listen to managing director and CEO Mark Diamond tell us about Antisense Therapeutics.
Antisense (ASX:ANP) is an Australian biopharma drug discovery and development company focused on creating, developing and commercialising novel antisense therapeutics for a variety of drug candidates including Duchenne Muscular Dystrophy, Multiple Sclerosis, and Acromegaly.
We gave the company’s managing director and CEO, Mark Diamond, 90 Seconds to provide and overview of Antisense, its recent drug developments and near term newsflow.
Note: Since the recording of this interview, Antisense has announced positive early results from the clinical trial of its ATL1102 drug.
Have a good idea for our next 90 Seconds With segment? Email us at [email protected].
UNLOCK INSIGHTS
Discover the untold stories of emerging ASX stocks.
Daily news and expert analysis, it's free to subscribe.
By proceeding, you confirm you understand that we handle personal information in accordance with our Privacy Policy.